EMA Recommends Extension of Indications for Sugemalimab By Ogkologos - October 28, 2025 163 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns monotherapy for the treatment of unresectable stage III NSCLC with no genomic alterations Source RELATED ARTICLESMORE FROM AUTHOR Perioperative Enfortumab Vedotin Plus Pembrolizumab Improves EFS, OS and pCR in Patients with MIBC Who Are Ineligible for Cisplatin EMA Recommends Extension of Therapeutic Indications for Niraparib / Abiraterone Acetate Lisocabtagene Maraleucel Shows Deep, Durable Responses in Patients with Relapsed or Refractory MZL After at Least Two Previous Lines of Systemic Therapy MOST POPULAR What to Know About Nonalcoholic Fatty Liver Disease (NAFLD) and Its... April 5, 2022 Opinion: ‘The idea that a tobacco company might profit off my... September 1, 2021 European Lung Cancer Congress 2025, Paris, France, 26-29 March 2025 March 20, 2025 97-Year-Old Cancer Survivor Credits Her Success With Wanting To Attend A... October 28, 2021 Load more HOT NEWS ¿Puede el uso de un microondas causar cáncer? Qué debo saber sobre la mastectomía con cierre plano después de... Curbing Production of Immune Checkpoint Protein Slows Liver Cancer in Mice EMA Recommends Extension of Therapeutic Indications for Durvalumab to Patients with...
